^
    Back
    Association details:
    Biomarker:UGT1A1*1*1
    Cancer:Rectal Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor) +
    irinotecan (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2021
    Title:

    Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.

    Published date:
    05/19/2021
    Excerpt:
    In the subgroup analysis, irinotecan showed a significant improvement in DFS (HR = 0.77, 95% CI 0.61-0.98) and OS (HR = 0.71, 95% CI 0.51-0.98) in UGT1A1*1*1 patients...The addition of irinotecan to standard capecitabine-based CRT had a tendency towards improving LC, DFS, and OS...UGT1A1*1*1 patients seem to benefit the most from irinotecan.
    DOI:
    10.1200/JCO.2021.39.15_suppl.3603
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1

    Excerpt:
    ...- UGT1A1*28 6/6 or 6/7...
    Trial ID:
    CinClare
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy

    Excerpt:
    ...UGT1A1's genotype of 6/6 or 6/7...
    Trial ID:
    NCT05688033